Insulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a 'peakless' profile (according to the insulin glargine package insert).
Insulin glargine is a long-acting, man-made version of human insulin. Insulin glargine works by replacing the insulin that is normally produced by the body and by helping move sugar from the blood into other body tissues where it is Used for energy. It also stops the liver from producing more sugar.
There are two type of Insulin glargine, which are Single Dose Vial and Pre-filled Syringe in the market. Considering its function, Insulin glargine is Used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also Used to treat people with type 2 diabetes (condition in which the body does not Used insulin normally and, therefore, cannot control the amount of sugar in the blood) who need insulin to control their diabetes.
We can see that there are just a few companies produce Insulin glargine, the production of them almost approach to 70% of whole market. They have seted plant in Japan, China, German, India, North Americato produce Insulin glargine, and China is the largest plant for Insulin glargine in the world and also the largest consumption country. As the amount of diabetes of increasing of China, the Chinese market will be bigger than North America.
The Industry is affected by the economic development level and policy, so it?s important to put an eye to economic indexes and leaders? prefer. With the global economic recovery, more and more people pay attention to care about personal health, especially in underdevelopment regions that have a large population and fast economic growth, the need of Insulin glargine will increase.
According to this study, over the next five years the Insulin Glargine market will register a 4.1% CAGR in terms of revenue, the global market size will reach USD 7240 million by 2024, from USD 5690 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Insulin Glargine business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Insulin Glargine market by product type, application, key manufacturers and key regions and countries.
This study considers the Insulin Glargine value and volume generated from the sales of the following segments-
Segmentation by product type- breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Single Dose Vial
Pre-filled Syringe
Segmentation by application- breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Treat type2 diabetes
Treat type1 diabetes
This report also splits the market by region- Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report- Breakdown data in in Chapter 3.
Sanofi-Aventis
Ganlee
Biocon
...
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Insulin Glargine consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Insulin Glargine market by identifying its various subsegments.
Focuses on the key global Insulin Glargine manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Insulin Glargine with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Insulin Glargine submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
